GeneDx (WGS) Projected to Post Earnings on Tuesday

Key Points

• GeneDx is set to release its Q3 2025 earnings on October 28, expecting earnings of $0.33 per share and revenues of $104.33 million.
• In its last report from July 29, GeneDx exceeded expectations with earnings of $0.50 per share and revenues of $102.69 million.
• Insider trading activity has shown significant sales, with Director Jason Ryan selling 38,072 shares and CEO Katherine Stueland selling 10,501 shares in recent months.

GeneDx (NASDAQ:WGS - Get Free Report) is anticipated to release its Q3 2025 results before the market opens on Tuesday, October 28th. Analysts expect GeneDx to post earnings of $0.33 per share and revenue of $104.3250 million for the quarter. GeneDx has set its FY 2025 guidance at EPS.Interested persons can check the company's upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Tuesday, October 28, 2025 at 8:30 AM ET.

GeneDx (NASDAQ:WGS - Get Free Report) last announced its quarterly earnings data on Tuesday, July 29th. The company reported $0.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.10 by $0.40. GeneDx had a return on equity of 16.51% and a net margin of 0.39%.The firm had revenue of $102.69 million during the quarter, compared to analysts' expectations of $86.00 million. On average, analysts expect GeneDx to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

GeneDx Trading Up 5.0%

Shares of NASDAQ:WGS opened at $127.03 on Tuesday. GeneDx has a 52-week low of $55.17 and a 52-week high of $136.00. The stock has a market cap of $3.65 billion, a price-to-earnings ratio of 2,540.60 and a beta of 1.98. The company has a quick ratio of 2.70, a current ratio of 2.87 and a debt-to-equity ratio of 0.19. The business has a 50-day moving average price of $123.07 and a 200-day moving average price of $96.73.

Insider Buying and Selling

In other GeneDx news, Director Jason Ryan sold 38,072 shares of the firm's stock in a transaction that occurred on Wednesday, August 27th. The stock was sold at an average price of $127.30, for a total value of $4,846,565.60. Following the sale, the director directly owned 103,284 shares of the company's stock, valued at approximately $13,148,053.20. This trade represents a 26.93% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Katherine Stueland sold 10,501 shares of the firm's stock in a transaction that occurred on Tuesday, September 16th. The shares were sold at an average price of $121.47, for a total value of $1,275,556.47. Following the completion of the sale, the chief executive officer directly owned 14,578 shares in the company, valued at approximately $1,770,789.66. The trade was a 41.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 556,371 shares of company stock valued at $67,489,314 in the last ninety days. Insiders own 29.60% of the company's stock.

Institutional Trading of GeneDx

Several institutional investors have recently bought and sold shares of WGS. Invesco Ltd. grew its holdings in GeneDx by 42.3% in the second quarter. Invesco Ltd. now owns 554,419 shares of the company's stock valued at $51,178,000 after purchasing an additional 164,840 shares during the period. Ameriprise Financial Inc. grew its holdings in GeneDx by 76.2% in the second quarter. Ameriprise Financial Inc. now owns 255,931 shares of the company's stock valued at $23,625,000 after purchasing an additional 110,684 shares during the period. Bank of America Corp DE grew its holdings in GeneDx by 156.8% in the second quarter. Bank of America Corp DE now owns 156,226 shares of the company's stock valued at $14,421,000 after purchasing an additional 95,389 shares during the period. AXA S.A. acquired a new stake in GeneDx in the second quarter valued at approximately $8,148,000. Finally, Raymond James Financial Inc. grew its holdings in GeneDx by 24.0% in the second quarter. Raymond James Financial Inc. now owns 413,223 shares of the company's stock valued at $38,145,000 after purchasing an additional 79,847 shares during the period. 61.72% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have recently issued reports on WGS. Piper Sandler raised their price objective on GeneDx from $120.00 to $140.00 and gave the stock an "overweight" rating in a research note on Thursday, September 11th. Zacks Research cut GeneDx from a "strong-buy" rating to a "hold" rating in a research note on Thursday, October 2nd. Wall Street Zen upgraded GeneDx from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Wells Fargo & Company raised their price objective on GeneDx from $78.00 to $95.00 and gave the stock an "equal weight" rating in a research note on Wednesday, July 30th. Finally, Weiss Ratings reiterated a "sell (d)" rating on shares of GeneDx in a research report on Wednesday, October 8th. Seven analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $109.78.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.